This PDF file includes:

• Supplementary Materials and Methods
• Fig. S1. Synthesis and characterization of a CLP conjugate.
• Fig. S2. Characterization of the CLP conjugate and its nanoparticles.
• Fig. S3. Luminescence properties of the CLP conjugate under different conditions.
• Fig. S4. Intracellular uptake of CLP nanoparticles and in vitro luminescence imaging in neutrophils.
• Fig. S5. In vivo imaging in different mouse models of inflammation.
• Fig. S6. The retention of CLP and luminol in the colon after enema administration in colitis mice.
• Fig. S7. In vitro antitumor activity of CLP nanoparticles.
• Fig. S8. Tumor therapy after intratumoral administration of CLP nanoparticles in mice bearing A549 xenografts.
• Fig. S9. In vivo pharmacokinetic, tissue distribution, and elimination profiles of CLP after intravenous administration.
• Fig. S10. Tissue distribution of CLP nanoparticles after intravenous administration in mice bearing A549 xenografts.
• Fig. S11. Tumor therapy after intravenous administration of CLP nanoparticles in mice bearing A549 xenografts.
• Fig. S12. Comparison of in vivo efficacy and safety of CLP nanoparticles with CDDP.
• Fig. S13. Safety study after intratumoral administration of CLP nanoparticles in A549 xenograft–bearing mice.
• Fig. S14. Safety profiles of CLP nanoparticles in A549 xenograft–bearing mice during and after 30 days of intravenous injection.
• Fig. S15. Acute toxicity evaluation of CLP nanoparticles after a single intravenous injection in healthy mice.
• Fig. S16. Mechanistic studies of in vitro antitumor activity of CLP nanoparticles in A549 cells.

Download PDF